How Will Pharma M&A Change In 2017?

Industry consultants survey the landscape for pharma deal making in 2017. More deals, higher prices and asset swaps as repatriated cash burns holes in US pharma's pockets are just for starters.

Curtain of darkness — How will the pharma M&A landscape change in 2017? • Source: Shutterstock

In October 2016, US companies unleashed an unprecedented wave of deals, making it the busiest month ever for domestic M&A, despite what had been a lackluster start to the year. This momentum for M&A is expected to continue into 2017 and, according to a recent report from Deloitte, which surveyed 1,000 executives to gauge their expectations for M&A activity, the magnitude of individual transactions this year will exceed the size of deals seen in 2016.

In the report titled M&A Trends: Year-end Report 2016, Deloitte found that 75% of respondents expected deal activity...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

06 Jun 2025

• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

04 Jun 2025

• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

04 Jun 2025

• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.